Mercedes Rincon

Co-founder of Mitotherapeutix and member of the SAB. Dr. Rincon is a Professor in Department of Immunology and Microbiology at the University of Colorado at Anschutz Medical Campus. She has over 149 publications, many in top journals such as Science, Nature, Cell, Immunity and her research has been well-funded for more than nineteen years. She has served in a number of review panels from the National Institute of Health (NIH), and is currently a standing member of CMI-A. She is member of Associate Editorial Board of several journals and has acted as a consultant for a number of pharma companies including Pharmacia, Novartis, Roche, ResVerlogix, and Genentech. Dr. Rincon is the primary inventor of two issued patents and four additional filed patents. Dr. Rincon is a national and internationally recognized immunologist with expertise in broad areas of research such as signaling pathways, allergy/asthma, arthritis and influenza infection. In addition, she has also been working for many years in molecular mechanisms of multidrug resistance in breast cancer, an area that brought her to the identification of MCJ as a key molecule in mitochondria function, and its role regulating chemotherapy response and metabolism. She joined the University of Vermont in 1996 as an Assistant Professor initially, Associate Professor with tenure later, and full Professor in Medicine since 2009 to 2019. She has established the SPARK-VT program at the University of Vermont to foster entrepreneurship in academic environments. Dr. Rincon received her Ph.D. from the University Autonoma of Madrid and trained as a postdoctoral fellow at Yale University School of Medicine.